Last reviewed · How we verify
CAN Community Health — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Bictegravir, emtricitabine, and tenofovir alafenamide | Bictegravir, emtricitabine, and tenofovir alafenamide | marketed | Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors) | HIV integrase, HIV reverse transcriptase | Infectious Disease / Virology |
Therapeutic area mix
- Infectious Disease / Virology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Charlotte-Paige Rolle, MD · 1 shared drug class
- Midland Research Group, Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for CAN Community Health:
- CAN Community Health pipeline updates — RSS
- CAN Community Health pipeline updates — Atom
- CAN Community Health pipeline updates — JSON
Cite this brief
Drug Landscape (2026). CAN Community Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/can-community-health. Accessed 2026-05-18.